<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05006352</url>
  </required_header>
  <id_info>
    <org_study_id>DNLI-F-0003</org_study_id>
    <secondary_id>2021-001766-37</secondary_id>
    <nct_id>NCT05006352</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study, Followed by an Open-Label Extension, to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Denali Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Denali Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind study of 28&#xD;
      days, followed by an 18-month open-label extension, designed to evaluate the safety,&#xD;
      pharmacokinetics (PK), and pharmacodynamics (PD) of DNL343 in participants with amyotrophic&#xD;
      lateral sclerosis (ALS)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 11, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) throughout the double-blind period</measure>
    <time_frame>28 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Maximum concentration (Cmax) of DNL343 in plasma</measure>
    <time_frame>19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Time to reach maximum concentration (tmax) of DNL343 in plasma</measure>
    <time_frame>19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Trough concentration (Ctrough) of DNL343 in plasma</measure>
    <time_frame>19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Area under the concentration-time curve from time zero to 24 hours (AUC24) of DNL343 in plasma</measure>
    <time_frame>19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid-to-plasma concentration ratio of DNL343 following multiple oral doses</measure>
    <time_frame>19 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>DNL343 (High Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DNL343 (Low Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DNL343</intervention_name>
    <description>Oral repeating dose</description>
    <arm_group_label>DNL343 (High Dose)</arm_group_label>
    <arm_group_label>DNL343 (Low Dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral repeating dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of sporadic or familial ALS&#xD;
&#xD;
          -  Less than 3 years since ALS symptom onset&#xD;
&#xD;
          -  Stable doses of approved ALS treatments (riluzole and/or edaravone) for at least 2&#xD;
             months prior to screening&#xD;
&#xD;
          -  Participants must be able to swallow the study intervention&#xD;
&#xD;
          -  Vital capacity &gt;50% predicted at screening&#xD;
&#xD;
          -  Women must have been surgically sterilized or be postmenopausal&#xD;
&#xD;
          -  Men, and sex partner if a woman of childbearing potential, must use highly effective&#xD;
             contraception&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Any history of unstable or poorly controlled psychiatric, endocrine, pulmonary,&#xD;
             cardiovascular, gastrointestinal, hepatic, pancreatic, renal, metabolic, hematologic,&#xD;
             immunologic, or allergic disease, or other major disorders&#xD;
&#xD;
          -  Positive serum pregnancy test or currently lactating or breastfeeding&#xD;
&#xD;
          -  History of malignancy within 5 years&#xD;
&#xD;
          -  History of clinically significant neurologic disorders other than ALS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Tsai, MD</last_name>
    <role>Study Director</role>
    <affiliation>Denali Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Human Drug Research (CHDR)</name>
      <address>
        <city>Leiden</city>
        <state>South Holland</state>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Project Manager</last_name>
      <phone>+31 71 5246 400</phone>
      <email>maurits.vissers@chdr.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 7, 2021</study_first_submitted>
  <study_first_submitted_qc>August 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

